Robert C.A.M. van Waardenburg

Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

Marc Maliepaard, Margôt A. van Gastelen, Akiko Tohgo et al. · PubMed · 2001 · 234 citations

Breast Oncology, Chemoprevention Strategy, Bcrp-mediated Resistance +17

Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines

Dick Pluim, Robert C.A.M. van Waardenburg, Jos H. Beijnen et al. · Cancer Chemotherapy and Pharmacology · 2004 · 96 citations

Oncogenic Agent, Medicine, Tumor Targeting +5

DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin

Mirjam Crul, Robert C.A.M. van Waardenburg, Suzanne Bocxe et al. · Biochemical Pharmacology · 2002 · 92 citations

Chromatin, Genome Instability, Cell Division +8

Structure of a SUMO-binding-motif Mimic Bound to Smt3p–Ubc9p: Conservation of a Non-covalent Ubiquitin-like Protein–E2 Complex as a Platform for Selective Interactions within a SUMO Pathway

David M. Duda, Robert C.A.M. van Waardenburg, Laura A. Borg et al. · Journal of Molecular Biology · 2007 · 64 citations · Full text

Selective Interactions, Protein Function, Biochemistry +9

32P-Postlabeling Assay for the Quantification of the Major Platinum-DNA Adducts

Dick Pluim, Marc Maliepaard, Robert C.A.M. van Waardenburg et al. · Analytical Biochemistry · 1999 · 53 citations

Chromatin, Biochemistry, Natural Sciences +8